184 related articles for article (PubMed ID: 29202622)
1. An inter-observer Ki67 reproducibility study applying two different assessment methods: on behalf of the Danish Scientific Committee of Pathology, Danish breast cancer cooperative group (DBCG).
Laenkholm AV; Grabau D; Møller Talman ML; Balslev E; Bak Jylling AM; Tabor TP; Johansen M; Brügmann A; Lelkaitis G; Di Caterino T; Mygind H; Poulsen T; Mertz H; Søndergaard G; Bruun Rasmussen B
Acta Oncol; 2018 Jan; 57(1):83-89. PubMed ID: 29202622
[TBL] [Abstract][Full Text] [Related]
2. Highly reproducible results of breast cancer biomarkers when analysed in accordance with national guidelines - a Swedish survey with central re-assessment.
Ekholm M; Grabau D; Bendahl PO; Bergh J; Elmberger G; Olsson H; Russo L; Viale G; Fernö M
Acta Oncol; 2015 Jul; 54(7):1040-8. PubMed ID: 25959664
[TBL] [Abstract][Full Text] [Related]
3. Standardized assessment of tumor-infiltrating lymphocytes in breast cancer: an evaluation of inter-observer agreement between pathologists.
Tramm T; Di Caterino T; Jylling AB; Lelkaitis G; Lænkholm AV; Ragó P; Tabor TP; Talman MM; Vouza E;
Acta Oncol; 2018 Jan; 57(1):90-94. PubMed ID: 29168428
[TBL] [Abstract][Full Text] [Related]
4. A Comparison of Visual Assessment and Automated Digital Image Analysis of Ki67 Labeling Index in Breast Cancer.
Zhong F; Bi R; Yu B; Yang F; Yang W; Shui R
PLoS One; 2016; 11(2):e0150505. PubMed ID: 26928407
[TBL] [Abstract][Full Text] [Related]
5. An interobserver reproducibility analysis of Ki67 visual assessment in breast cancer.
Shui R; Yu B; Bi R; Yang F; Yang W
PLoS One; 2015; 10(5):e0125131. PubMed ID: 25932921
[TBL] [Abstract][Full Text] [Related]
6. Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration.
Leung SCY; Nielsen TO; Zabaglo LA; Arun I; Badve SS; Bane AL; Bartlett JMS; Borgquist S; Chang MC; Dodson A; Ehinger A; Fineberg S; Focke CM; Gao D; Gown AM; Gutierrez C; Hugh JC; Kos Z; Laenkholm AV; Mastropasqua MG; Moriya T; Nofech-Mozes S; Osborne CK; Penault-Llorca FM; Piper T; Sakatani T; Salgado R; Starczynski J; Sugie T; van der Vegt B; Viale G; Hayes DF; McShane LM; Dowsett M;
Histopathology; 2019 Aug; 75(2):225-235. PubMed ID: 31017314
[TBL] [Abstract][Full Text] [Related]
7. An interobserver reproducibility analysis of size-set semiautomatic counting for Ki67 assessment in breast cancer.
Wang YX; Wang YY; Yang CG; Bu H; Yang WT; Wang L; Xu WM; Zhao XL; Zhao WX; Li L; Song SL; Yang JL
Breast; 2020 Feb; 49():225-232. PubMed ID: 31911370
[TBL] [Abstract][Full Text] [Related]
8. Quality assurance trials for Ki67 assessment in pathology.
Raap M; Ließem S; Rüschoff J; Fisseler-Eckhoff A; Reiner A; Dirnhofer S; von Wasielewski R; Kreipe H
Virchows Arch; 2017 Oct; 471(4):501-508. PubMed ID: 28497316
[TBL] [Abstract][Full Text] [Related]
9. Sequential immunohistochemistry and virtual image reconstruction using a single slide for quantitative KI67 measurement in breast cancer.
Serna G; Simonetti S; Fasani R; Pagliuca F; Guardia X; Gallego P; Jimenez J; Peg V; Saura C; Eppenberger-Castori S; Ramon Y Cajal S; Terracciano L; Nuciforo P
Breast; 2020 Oct; 53():102-110. PubMed ID: 32707454
[TBL] [Abstract][Full Text] [Related]
10. St Gallen 2015 subtyping of luminal breast cancers: impact of different Ki67-based proliferation assessment methods.
Focke CM; van Diest PJ; Decker T
Breast Cancer Res Treat; 2016 Sep; 159(2):257-63. PubMed ID: 27558625
[TBL] [Abstract][Full Text] [Related]
11. Interlaboratory variability of Ki67 staining in breast cancer.
Focke CM; Bürger H; van Diest PJ; Finsterbusch K; Gläser D; Korsching E; Decker T;
Eur J Cancer; 2017 Oct; 84():219-227. PubMed ID: 28829990
[TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
[TBL] [Abstract][Full Text] [Related]
13. Luminal A versus luminal B breast cancer: MammaTyper mRNA versus immunohistochemical subtyping with an emphasis on standardised Ki67 labelling-based or mitotic activity index-based proliferation assessment.
Finsterbusch K; Decker T; van Diest PJ; Focke CM
Histopathology; 2020 Apr; 76(5):650-660. PubMed ID: 31846096
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the Ki67 labeling index: a Japanese validation ring study.
Niikura N; Sakatani T; Arima N; Ohi Y; Honma N; Kanomata N; Yoshida K; Kadoya T; Tamaki K; Kumaki N; Iwamoto T; Sugie T; Moriya T
Breast Cancer; 2016 Jan; 23(1):92-100. PubMed ID: 24794952
[TBL] [Abstract][Full Text] [Related]
15. The additional value of ONEST (Observers Needed to Evaluate Subjective Tests) in assessing reproducibility of oestrogen receptor, progesterone receptor, and Ki67 classification in breast cancer.
Cserni B; Bori R; Csörgő E; Oláh-Németh O; Pancsa T; Sejben A; Sejben I; Vörös A; Zombori T; Nyári T; Cserni G
Virchows Arch; 2021 Dec; 479(6):1101-1109. PubMed ID: 34415429
[TBL] [Abstract][Full Text] [Related]
16. Good staining quality ensuring the reproducibility of Ki67 assessment.
Wang YH; Lai CR; Lien HC; Hsu CY
J Clin Pathol; 2020 Jul; 73(7):413-417. PubMed ID: 31796636
[TBL] [Abstract][Full Text] [Related]
17. Proliferation assessment in breast carcinomas using digital image analysis based on virtual Ki67/cytokeratin double staining.
Røge R; Riber-Hansen R; Nielsen S; Vyberg M
Breast Cancer Res Treat; 2016 Jul; 158(1):11-19. PubMed ID: 27283833
[TBL] [Abstract][Full Text] [Related]
18. The region-of-interest size impacts on Ki67 quantification by computer-assisted image analysis in breast cancer.
Christgen M; von Ahsen S; Christgen H; Länger F; Kreipe H
Hum Pathol; 2015 Sep; 46(9):1341-9. PubMed ID: 26206765
[TBL] [Abstract][Full Text] [Related]
19. Digital image analysis of Ki67 proliferation index in breast cancer using virtual dual staining on whole tissue sections: clinical validation and inter-platform agreement.
Koopman T; Buikema HJ; Hollema H; de Bock GH; van der Vegt B
Breast Cancer Res Treat; 2018 May; 169(1):33-42. PubMed ID: 29349710
[TBL] [Abstract][Full Text] [Related]
20. Reliability of the Ki67-Labelling Index in Core Needle Biopsies of Luminal Breast Cancers is Unaffected by Biopsy Volume.
Focke CM; Decker T; van Diest PJ
Ann Surg Oncol; 2017 May; 24(5):1251-1257. PubMed ID: 28008571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
